Zeke Capital Advisors LLC Acquires 21,872 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Zeke Capital Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 154.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 36,044 shares of the biopharmaceutical company’s stock after purchasing an additional 21,872 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Gilead Sciences were worth $2,342,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. First Financial Corp IN boosted its position in shares of Gilead Sciences by 286.4% during the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 401 shares during the last quarter. M&R Capital Management Inc. boosted its position in shares of Gilead Sciences by 83.3% during the fourth quarter. M&R Capital Management Inc. now owns 550 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 250 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Gilead Sciences during the third quarter valued at approximately $40,000. Front Row Advisors LLC boosted its position in shares of Gilead Sciences by 286.0% during the second quarter. Front Row Advisors LLC now owns 691 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 512 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Gilead Sciences by 30.7% during the third quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 194 shares during the last quarter. 79.28% of the stock is owned by institutional investors.

GILD has been the topic of several research analyst reports. Credit Suisse Group cut Gilead Sciences from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $67.00 to $63.00 in a research report on Friday, December 13th. Guggenheim set a $86.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 25th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Oppenheimer upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating in a research note on Friday, January 3rd. Finally, Cowen reissued a “buy” rating and issued a $85.00 price target on shares of Gilead Sciences in a report on Thursday, January 2nd. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $78.91.

In related news, EVP Brett A. Pletcher sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $64.91, for a total value of $649,100.00. Following the completion of the transaction, the executive vice president now directly owns 17,064 shares of the company’s stock, valued at approximately $1,107,624.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $66.85, for a total transaction of $1,002,750.00. Following the completion of the transaction, the executive vice president now directly owns 32,064 shares of the company’s stock, valued at $2,143,478.40. The disclosure for this sale can be found here. Insiders have sold a total of 45,622 shares of company stock valued at $2,986,438 over the last three months. Insiders own 0.20% of the company’s stock.

Shares of Gilead Sciences stock traded down $0.55 on Friday, reaching $62.65. 3,458,522 shares of the company traded hands, compared to its average volume of 6,689,442. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $70.50. The company has a 50 day moving average of $65.96 and a 200 day moving average of $65.23. The firm has a market capitalization of $79.65 billion, a PE ratio of 10.19, a PEG ratio of 3.90 and a beta of 1.11. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.96 and a quick ratio of 2.87.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The firm had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the prior year, the firm earned $1.84 EPS. The company’s revenue was up .1% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.63 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.02%. The ex-dividend date was Thursday, December 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is meant by buying and selling pressure?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.